Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
OwnerBeth A. Burnside, Rong-Kun Chang +1inventors
InventorsBeth A. Burnside, Rong-Kun Chang, Xiaodi Guo
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Claims73
A pharmaceutical composition, comprising:
- (a) at least one pharmaceutically active agent that is pH dependent:
- (b) at least one non-pH dependent sustained release agent;
- and
- (c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.
The composition of claim I wherein said pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 is an agent that maintains an acidic microenvironment in the composition.
A pharmaceutical composition, comprising:
- (a) anagrelide;
- (b) polyethylene oxide;
- (c) dibasic calcium phosphate;
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- and
- (g) magnesium stearate.
A pharmaceutical composition, comprising:
- (h) Anagrelide hydrochloride;
- (i) polyethylene oxide;
- (j) dibasic calcium phosphate;
- (k) microcrystalline cellulose;
- (l) a methacrylic acid copolymer;
- (m) glyceryl behenate;
- and
- (n) magnesium stearate.
A pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
A pharmaceutical composition, comprising:
- (a) guanfacine;
- (b) Hydroxypropyl Methylcellulose
- (c) Ammonio Methacrylate Copolymer
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- and
- (g) Fumaric Acid,
- (h) Lactose Monohydrate
- (i) Povidone;
- and
- (j) Crospovidone Granulated Blend.
A pharmaceutical composition comprising:
- (a) Guanfacine hydrochloride;
- (b) Hydroxypropyl Methylcellulose
- (c) Ammonio Methacrylate Copolymer
- (d) microcrystalline cellulose;
- (e) a methacrylic acid copolymer;
- (f) glyceryl behenate;
- and
- (g) Fumaric Acid,
- (h) Lactose Monohydrate
- (i) Povidone;
- and
- (j) Crospovidone Granulated Blend.
Dependencies are inferred from the claim text.